Login / Signup

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.

Kazuhito YamamotoAtsushi ShinagawaCourtney D DiNardoKeith W PratzKenichi IshizawaToshihiro MiyamotoNorio KomatsuYasuhiro NakashimaChikashi YoshidaNoriko FukuharaKensuke UsukiTakahiro YamauchiNoboru AsadaNorio AsouIlseung ChoiYasushi MiyazakiHideyuki HondaSumiko OkuboMisaki KurokawaYing ZhouJiuhong ZhaJalaja PotluriItaru Matsumura
Published in: Japanese journal of clinical oncology (2021)
This Japanese subgroup analysis of VIALE-A demonstrates comparable safety and efficacy outcomes compared with the global study and supports venetoclax-azacitidine as first-line standard-of-care for Japanese treatment-naive patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Keyphrases